The Fund has published its 4 principles. This is the 4th of them:
Antibiotic developer companies should be supported to fulfill their role in achieving access and appropriate use. Through its investments and capability platform, which provides connection to a diverse set of expertise from both industry and non-industry partners, the AMR Action Fund will provide vital support to portfolio companies to ensure activities are aligned with Access and Appropriate Use principles. The AMR Action Fund will work with portfolio companies to build access and appropriate use into antibiotic development strategies, and support companies to develop and make public Access and Appropriate Use Plans when assets are in Phase III clinical trials. These plans will include the strategies to be adopted by portfolio companies to promote access and appropriate use, including how they will work with partners in low- and middle-income countries, in line with guidance to be developed by the AMR Action Fund. The AMR Action Fund will monitor progress against these plans as part of its regular engagement with portfolio companies and will factor this into potential follow-on investments.
So the Fund is telling what it would be doing to help ATH with its PBT2 and the Fund has experts in all these fields needed and ATH has nothing in this field. The Fund has also all the money needed to do these things. We know that ATH has the money only for neurodegenerative drugs and it has been looking for somebody to support PBT2.
If you want to read all of the principles, go here: About Us - AMR Action Fund
ATH Price at posting:
0.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)